STUDY ON THE PREVALENCE OF FETAL GROWTH RESTRICTION, ASSOCIATED FACTORS, AND PREGNANCY OUTCOMES IN PREGNANT WOMEN AT PHUONG CHAU INTERNATIONAL HOSPITAL, 2025 – 2026
Main Article Content
Abstract
Background: Fetal growth restriction (FGR) is a major obstetric complication affecting approximately 7–10% of pregnancies worldwide and is associated with increased risks of perinatal mortality, neonatal respiratory distress, metabolic disorders, and long-term neurodevelopmental impairment.
Objective: To determine the prevalence of fetal growth restriction, identify associated factors, and evaluate pregnancy outcomes among pregnant women at Phuong Chau International Hospital during 2025–2026.
Methods: A cross-sectional analytical study was conducted on 772 pregnant women from 14 weeks of gestation who received antenatal care at Phuong Chau International Hospital. Pregnancies diagnosed with FGR were subsequently followed longitudinally until delivery to assess pregnancy outcomes. Data were analyzed using Stata 15.1. Logistic regression analysis was performed to identify factors associated with FGR.
Results: The prevalence of FGR was 7.4%. Early-onset FGR (<32 weeks) accounted for 19.3% of cases, whereas late-onset FGR (≥32 weeks) accounted for 80.7%. Independent factors associated with FGR included maternal hypertension (OR=13.8; p=0.014), diabetes mellitus (OR=25.5; p<0.001), pre-pregnancy body mass index (BMI) <18.5 kg/m² (OR=159; p<0.001), and abnormal placental position (OR=16.7; p=0.002). Among pregnancies complicated by FGR, the rate of low birth weight (<2500 g) was 64.9%.
Conclusion: FGR remains a significant obstetric condition with a high proportion of low birth weight newborns. Early screening and close monitoring are essential, particularly among pregnant women with hypertension, diabetes, low pre-pregnancy BMI, and placental abnormalities.
Keywords
fetal growth restriction, pregnancy outcome, low birth weight, risk factors
Article Details
References
2. Nguyen, D. V, (2019), “Thai giới hạn tăng trưởng những vấn đề lưu ý trong chẩn đoán và theo dõi”. Tạp chí Phụ sản, 16(4), tr. 35-39
3. Gaccioli, F, Aye, I. L. M. H, Sovio, U. Charnock-Jones, D. S. & Smith, G. C. S, (2018), “Screening for fetal growth restriction using fetal biometry combined with maternal biomarkers”, American Journal of Obstetrics and Gynecology, 218(2), pp. S725-S737.
4. John C. Kingdom, MD FRCSC, Toronto, ON Eran Ashwal, M. F, Hamilton, ON Andrea Lausman, et al, (2023), “Fetal Growth Restriction: Screening, Diagnosis, and Management in Singleton Pregnancies”, SOGC Guideline 2023 Sinai Health system, pp. 1-26.
5. Leavitt, K, Odibo, L, Nwabuobi, C, Tuuli, M. G. & Odibo, A, (2021), “The value of introducing cerebroplacental ratio (CPR) versus umbilical artery (UA) Doppler alone for the prediction of neonatal small for gestational age (SGA) and short-term adverse outcomes”, J Matern Fetal Neonatal Med, 34(10), pp. 1565-1569.
6. Lees, C. C, Romero, R, Stampalija, T, Dall’Asta, A, DeVore, G. A, Prefumo, F, et al, (2022), “Clinical Opinion: The diagnosis and management of suspected fetal growth restriction: an evidence-based approach”, Am J Obstet Gynecol, 226(3), pp. 366-378.
7. Lees, C. C, Stampalija, T, Baschat, A, da Silva Costa, F, Ferrazzi, E, Figueras, F, et al, (2020), “ISUOG Practice Guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction”, Ultrasound Obstet Gynecol, 56(2), pp. 298-312.
8. Rodriguez-Sibaja, M. J, Lopez-Diaz, A. J, Valdespino-Vazquez, M. Y, Acevedo-Gallegos S. Amaya-Guel, Y,C amarena-Cabrera, D. M., et al, (2024), “Placental pathology lesions: International Society for Ultrasound in Obstetrics and Gynecology vs Society for Maternal-Fetal Medicine fetal growth restriction definitions”, Am J Obstet Gynecol MFM, 6(8), pp. 101422.